The Follow-up in sporadic Cerebral Amyloid Angiopathy Study

The Follow-up in sporadic Cerebral Amyloid Angiopathy Study - FOCAS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52554

Enrollment

190

Registered

2018-02-07

Start date

2018-02-14

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAA sCAA sporadic cerebral amyloid angiopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 50y 2. Ability and willingness to provide written informed consent 3. Probable CAA based on the Boston criteria 2.0, and no family history of HCHWA-D, including CAA related inflammation Healthy controls: age- and sex matched to the sCAA group, no history of neurological disease and free of substantial memory complaints

Exclusion criteria

Exclusion criteria: 1. Contra-indications for 3T/7T MRI as determined by the 7Tesla safety committee (exclusion for a subpart of the study). 2. Contraindications for lumbar puncture (exclusion for a subpart of the study).

Design outcomes

Primary

Measure	Time frame
The main parameters are microvascular CAA markers on 3T-MRI and 7T-MRI, changes in CSF, recurrence ICH rate and clinical outcome.	—

Secondary

Measure	Time frame
Other studyparameters will include: date of birth, gender, medical history, consumption of alcohol/caffeïne/drugs, smoking, medication use, cardiovascular risk factors, neurological history, BMI, blood pressure and APOE genotype.	—

Countries

Netherlands

Outcome results